Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells.
However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, and designing appropriate combination therapies might help to overcome BCG resistance and redirect neutrophils against bladder cancer cells.
Written by:
Jinesh G G, Kamat AM Are you the author?
Department of Urology, Unit 1373; The University of Texas MD Anderson Cancer Center; Houston, TX USA
Reference: Oncoimmunology. 2012 Oct 1;1(7):1161-1162
doi: 10.4161/onci.20928
PubMed Abstract
PMID: 23170264
